{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:24:12Z","timestamp":1792686252530,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eprac.2025.12.002","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:15:54Z","timestamp":1765844154000},"page":"401-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thyroid-Stimulating Hormone Suppression Therapy in Thyroid Cancer: Balancing Benefits and Harms"],"prefix":"10.1016","volume":"32","author":[{"given":"Reza","family":"Pishdad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0566-6771","authenticated-orcid":false,"given":"Sara","family":"Ahmadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eprac.2025.12.002_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/thy.2021.0662","article-title":"Thyroid cancer incidence and mortality trends in the United States: 2000-2018","volume":"32","author":"Megwalu","year":"2022","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.eprac.2025.12.002_bib2","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/cen.12027","article-title":"Higher TSH level is a risk factor for differentiated thyroid cancer","volume":"78","author":"Kim","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.eprac.2025.12.002_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188123","article-title":"Serum TSH levels as a predictor of malignancy in thyroid nodules: a prospective study","volume":"12","author":"Golbert","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.002_bib5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7754","article-title":"Association of thyrotropin suppression with survival outcomes in patients with Intermediate- and high-risk differentiated thyroid cancer","volume":"2","author":"Klubo-Gwiezdzinska","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.002_bib6","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1210\/JC.2015-1346","article-title":"Long-Term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS registry analysis 1987-2012","volume":"100","author":"Carhill","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2025.12.002_bib7","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1177\/10507256251363120","article-title":"2025 American Thyroid Association Management Guidelines for adult patients with differentiated thyroid cancer","volume":"35","author":"Ringel","year":"2025","journal-title":"Thyroid. official journal Am Thyroid Asso"},{"issue":"7","key":"10.1016\/j.eprac.2025.12.002_bib8","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2025.0033","article-title":"NCCN Guidelines(R) insights: Thyroid Carcinoma, Version 1.2025","volume":"23","author":"Haddad","year":"2025","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"10.1016\/j.eprac.2025.12.002_bib9","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1210\/jc.2017-02629","article-title":"Risk factors for cardiovascular disease among thyroid cancer survivors: findings from the Utah cancer survivors Study","volume":"103","author":"Park","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.002_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-18-0551","article-title":"Increased cardiovascular risk in thyroid cancer patients taking levothyroxine: a nationwide cohort study in Korea","volume":"180","author":"Suh","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"32","key":"10.1016\/j.eprac.2025.12.002_bib11","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1200\/JCO.2013.49.1043","article-title":"Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study","volume":"31","author":"Klein Hesselink","year":"2013","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.eprac.2025.12.002_bib12","first-page":"3655","article-title":"Effect of TSH suppression therapy on bone mineral density in differentiated thyroid cancer: a systematic review and meta-analysis","volume":"106","author":"Ku","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.002_bib13","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3390\/jcm10091964","article-title":"Measurements of bone health after thyroid-stimulating suppression therapy in postmenopausal women with differentiated thyroid carcinoma: bone mineral density versus the trabecular bone Score","volume":"10","author":"Chung","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.002_bib14","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1634\/theoncologist.2019-0234","article-title":"Risk of osteoporosis and fractures in patients with thyroid cancer: a case-control study in U.S. veterans","volume":"24","author":"Papaleontiou","year":"2019","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.eprac.2025.12.002_bib15","first-page":"4318","article-title":"Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer","volume":"81","author":"Pujol","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.12.002_bib16","first-page":"4549","article-title":"Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma","volume":"84","author":"Wang","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"issue":"7-8","key":"10.1016\/j.eprac.2025.12.002_bib17","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/078538902321117760","article-title":"Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer","volume":"34","author":"McGriff","year":"2002","journal-title":"Ann Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.002_bib18","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1089\/thy.2023.0711","article-title":"The effect of thyrotropin suppression on survival outcomes in patients with differentiated thyroid cancer: a systematic review and meta-analysis","volume":"34","author":"Gubbi","year":"2024","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.eprac.2025.12.002_bib19","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1210\/jc.2010-0161","article-title":"Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial","volume":"95","author":"Sugitani","year":"2010","journal-title":"J Clin Endocrinol Metabol"},{"issue":"3","key":"10.1016\/j.eprac.2025.12.002_bib20","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/thy.2014.0287","article-title":"Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma","volume":"25","author":"Wang","year":"2015","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.002_bib21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/thy.2024.0330","article-title":"Association between serum thyrotropin and cancer recurrence in differentiated thyroid cancer: a population-based retrospective cohort Study","volume":"35","author":"Qiang","year":"2025","journal-title":"Thyroid"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.002_bib22","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1507\/endocrj.K10E-019","article-title":"Prognosis and prognostic factors of patients with papillary carcinoma showing distant metastasis at surgery (M1 patients) in Japan","volume":"57","author":"Ito","year":"2010","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.eprac.2025.12.002_bib23","doi-asserted-by":"crossref","first-page":"E152","DOI":"10.25011\/cim.v35i3.16591","article-title":"Prevalence of atrial fibrillation in patients taking TSH suppression therapy for management of thyroid cancer","volume":"35","author":"Abonowara","year":"2012","journal-title":"Clin Invest Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.002_bib24","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s00268-019-05249-8","article-title":"Cardiovascular incidence in 6900 patients with differentiated thyroid cancer: a Swedish nationwide Study","volume":"44","author":"Zoltek","year":"2020","journal-title":"World J Surg"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.002_bib25","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/cen.13519","article-title":"Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer","volume":"88","author":"Pajam\u00e4ki","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.eprac.2025.12.002_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.991876","article-title":"Meta-analysis of TSH suppression therapy and the risk of cardiovascular events after thyroid cancer surgery","volume":"13","author":"Yang","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.002_bib27","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/07435800.2024.2383669","article-title":"Do different TSH suppression levels effect heart rate variability and QT dispersions in patients with differentiated thyroid cancer?","volume":"50","author":"\u00c7elik","year":"2025","journal-title":"Endocr Res"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.002_bib28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.eprac.2023.11.006","article-title":"Effect of thyroid-stimulating hormone suppression therapy on cardiac structure and function in patients with differentiated thyroid cancer after thyroidectomy: a systematic review and meta-analysis","volume":"30","author":"Zhang","year":"2024","journal-title":"Endocr Pract"},{"issue":"6","key":"10.1016\/j.eprac.2025.12.002_bib29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1055\/a-2084-3408","article-title":"Cardiovascular outcomes of differentiated thyroid cancer patients on long term TSH suppression: a systematic review and meta-analysis","volume":"55","author":"Yu","year":"2023","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.eprac.2025.12.002_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1004962","article-title":"Application and prospect of trabecular bone score in differentiated thyroid cancer patients receiving thyrotropin suppression therapy","volume":"13","author":"Ran","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.002_bib31","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1210\/endo.134.1.8275930","article-title":"Osteoblasts mediate thyroid hormone stimulation of osteoclastic bone resorption","volume":"134","author":"Britto","year":"1994","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.eprac.2025.12.002_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0092-8674(03)00771-2","article-title":"TSH is a negative regulator of skeletal remodeling","volume":"115","author":"Abe","year":"2003","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.eprac.2025.12.002_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043007","article-title":"Effects of thyroid-stimulating hormone suppression after thyroidectomy for thyroid cancer on bone mineral density in postmenopausal women: a systematic review and meta-analysis","volume":"11","author":"Kwak","year":"2021","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.002_bib34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12020-022-03186-6","article-title":"Effects of TSH suppressive therapy on bone mineral density (BMD) and bone turnover markers (BTMs) in patients with differentiated thyroid cancer in Northeast China: a prospective controlled cohort study","volume":"79","author":"Wang","year":"2023","journal-title":"Endocrine"},{"issue":"16","key":"10.1016\/j.eprac.2025.12.002_bib35","doi-asserted-by":"crossref","first-page":"5746","DOI":"10.1002\/cam4.3200","article-title":"Trabecular bone deterioration in differentiated thyroid cancer: impact of long-term TSH suppressive therapy","volume":"9","author":"Hawkins Carranza","year":"2020","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.002_bib36","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12020-018-1671-8","article-title":"Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy","volume":"62","author":"De Mingo Dominguez","year":"2018","journal-title":"Endocrine"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.002_bib37","first-page":"78","article-title":"The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma","volume":"102","author":"Moon","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.12.002_bib38","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/cen.14698","article-title":"Bone-density testing interval and transition to osteoporosis in differentiated thyroid carcinoma patients on TSH suppression therapy","volume":"97","author":"Park","year":"2022","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.eprac.2025.12.002_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.769074","article-title":"Effect of thyroid-stimulating hormone suppression on muscle function after total thyroidectomy in patients with thyroid cancer","volume":"12","author":"Lee","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.002_bib40","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/thy.2020.0929","article-title":"Competing causes of death in older adults with thyroid cancer","volume":"31","author":"Papaleontiou","year":"2021","journal-title":"Thyroid"},{"issue":"9","key":"10.1016\/j.eprac.2025.12.002_bib41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1089\/thy.2021.0033","article-title":"Thyrotropin suppression for papillary thyroid cancer: a physician survey study","volume":"31","author":"Papaleontiou","year":"2021","journal-title":"Thyroid"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25013199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25013199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:13:52Z","timestamp":1781525632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25013199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S1530891X25013199"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.12.002","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thyroid-Stimulating Hormone Suppression Therapy in Thyroid Cancer: Balancing Benefits and Harms","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}